164 related articles for article (PubMed ID: 37823394)
1. M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator.
Wijnands C; Langerhorst P; Noori S; Keizer-Garritsen J; Wessels HJCT; Gloerich J; Bonifay V; Caillon H; Luider TM; van Gool AJ; Dejoie T; VanDuijn MM; Jacobs JFM
Clin Chem Lab Med; 2024 Feb; 62(3):540-550. PubMed ID: 37823394
[TBL] [Abstract][Full Text] [Related]
2. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
3. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Fan H; Wang B; Shi L; Pan N; Yan W; Xu J; Gong L; Li L; Liu Y; Du C; Cui J; Zhu G; Deng S; Sui W; Xu Y; Yi S; Hao M; Zou D; Chen X; Qiu L; An G
Clin Cancer Res; 2024 Mar; 30(6):1131-1142. PubMed ID: 38170583
[TBL] [Abstract][Full Text] [Related]
4. An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients.
Wijnands C; Armony G; Noori S; Gloerich J; Bonifay V; Caillon H; Luider TM; Brehmer S; Pfennig L; Srikumar T; Trede D; Kruppa G; Dejoie T; van Duijn MM; van Gool AJ; Jacobs JFM; Wessels HJCT
Clin Chem Lab Med; 2024 Jun; ():. PubMed ID: 38872409
[TBL] [Abstract][Full Text] [Related]
5. LC-MS/MS determination of a human mAb drug candidate in rat serum using an isotopically labeled universal mAb internal standard.
Li W; Lin H; Fu Y; Flarakos J
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Feb; 1044-1045():166-176. PubMed ID: 28113139
[TBL] [Abstract][Full Text] [Related]
6. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
Guan L; Su W; Zhong J; Qiu L
Clin Chim Acta; 2024 Jan; 552():117623. PubMed ID: 37924928
[TBL] [Abstract][Full Text] [Related]
7. Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma.
Langerhorst P; Brinkman AB; VanDuijn MM; Wessels HJCT; Groenen PJTA; Joosten I; van Gool AJ; Gloerich J; Scheijen B; Jacobs JFM
Clin Chem; 2021 Jun; 67(6):867-875. PubMed ID: 33709101
[TBL] [Abstract][Full Text] [Related]
8. A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM).
Liyasova M; McDonald Z; Taylor P; Gorospe K; Xu X; Yao C; Liu Q; Yang L; Atenafu EG; Piza G; Ma B; Reece D; Trudel S
Clin Cancer Res; 2021 Sep; 27(18):5028-5037. PubMed ID: 34210683
[TBL] [Abstract][Full Text] [Related]
9. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
[TBL] [Abstract][Full Text] [Related]
10. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.
Zajec M; Jacobs JFM; Groenen PJTA; de Kat Angelino CM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
J Proteome Res; 2018 Mar; 17(3):1326-1333. PubMed ID: 29424538
[TBL] [Abstract][Full Text] [Related]
11. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.
Bergen HR; Dasari S; Dispenzieri A; Mills JR; Ramirez-Alvarado M; Tschumper RC; Jelinek DF; Barnidge DR; Murray DL
Clin Chem; 2016 Jan; 62(1):243-51. PubMed ID: 26430073
[TBL] [Abstract][Full Text] [Related]
12. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
[TBL] [Abstract][Full Text] [Related]
13. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
14. Metrological traceability in mass spectrometry-based targeted protein quantitation: a proof-of-principle study for serum apolipoproteins A-I and B100.
Smit NP; Romijn FP; van den Broek I; Drijfhout JW; Haex M; van der Laarse A; van der Burgt YE; Cobbaert CM
J Proteomics; 2014 Sep; 109():143-61. PubMed ID: 24972322
[TBL] [Abstract][Full Text] [Related]
15. Advances in minimal residual disease monitoring in multiple myeloma.
Wijnands C; Noori S; Donk NWCJV; VanDuijn MM; Jacobs JFM
Crit Rev Clin Lab Sci; 2023 Nov; 60(7):518-534. PubMed ID: 37232394
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
17. A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma.
Muccio S; Hirtz C; Descloux S; Fedeli O; Macé S; Lehmann S; Vialaret J
Clin Chim Acta; 2024 Jan; 552():117634. PubMed ID: 37980975
[TBL] [Abstract][Full Text] [Related]
18. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
[TBL] [Abstract][Full Text] [Related]
19. Integrating Serum Protein Electrophoresis with Mass Spectrometry, A New Workflow for M-Protein Detection and Quantification.
Zajec M; Jacobs JFM; de Kat Angelino CM; Dekker LJM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
J Proteome Res; 2020 Jul; 19(7):2845-2853. PubMed ID: 31895568
[TBL] [Abstract][Full Text] [Related]
20. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
